Based on the LAVA THERAP. B.V. EO-12 stock forecast from 0 analysts, the average analyst target price for LAVA THERAP. B.V. EO-12 is not available over the next 12 months. LAVA THERAP. B.V. EO-12’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of LAVA THERAP. B.V. EO-12 is Slightly Bullish , which is based on 3 positive signals and 2 negative signals. At the last closing, LAVA THERAP. B.V. EO-12’s stock price was EUR 0.94. LAVA THERAP. B.V. EO-12’s stock price has changed by +0.00% over the past week, -36.05% over the past month and -30.88% over the last year.
No recent analyst target price found for LAVA THERAP. B.V. EO-12
No recent average analyst rating found for LAVA THERAP. B.V. EO-12
Company Overview LAVA THERAP. B.V. EO-12
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Read Less
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to el...Read More
Frequently Asked Questions About LAVA THERAP. B.V. EO-12 (4PKB:F) Stock
Stock Target Advisor's fundamental analysis for LAVA THERAP. B.V. EO-12's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4PKB:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4PKB:F's stock to indicate what its average analyst target is.
4PKB:F stock's Price/Earning ratio is 0.38.
Our analysis grades 4PKB:F stock's Price / Earning ratio at A. This means that 4PKB:F stock's Price/Earning ratio is above 6.000000000000005% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4PKB:F may be undervalued for its sector.
The last closing price of 4PKB:F's stock was EUR 0.94.
The most recent market capitalization for 4PKB:F is EUR 0.03B.
Unfortunately we do not have enough analyst data on 4PKB:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains LAVA THERAP. B.V. EO-12's stock.
As per our most recent records LAVA THERAP. B.V. EO-12 has 37 Employees.
LAVA THERAP. B.V. EO-12's registered address is Yalelaan 62, Utrecht, Netherlands, 3584 CM.
You can get more information about it from LAVA THERAP. B.V. EO-12's website at https://www.lavatherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About LAVA THERAP. B.V. EO-12 (4PKB:F) Stock
Stock Target Advisor's fundamental analysis for LAVA THERAP. B.V. EO-12's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4PKB:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4PKB:F's stock to indicate what its average analyst target is.
4PKB:F stock's Price/Earning ratio is 0.38.
Our analysis grades 4PKB:F stock's Price / Earning ratio at A. This means that 4PKB:F stock's Price/Earning ratio is above 6.000000000000005% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4PKB:F may be undervalued for its sector.
The last closing price of 4PKB:F's stock was EUR 0.94.
The most recent market capitalization for 4PKB:F is EUR 0.03B.
Unfortunately we do not have enough analyst data on 4PKB:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains LAVA THERAP. B.V. EO-12's stock.
As per our most recent records LAVA THERAP. B.V. EO-12 has 37 Employees.
LAVA THERAP. B.V. EO-12's registered address is Yalelaan 62, Utrecht, Netherlands, 3584 CM.
You can get more information about it from LAVA THERAP. B.V. EO-12's website at https://www.lavatherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4PKB:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
